Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3127 - Prognostic Value of Neutrophil-Lymphocyte Ratio in First Line Treatment for Metastatic Pancreatic Adenocarcinoma


09 Sep 2017


Poster display session


Young Soo Rho


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


Y.S. Rho1, J. Ranger2, S. Hamalova2, I. Barrera2, A. Mamo2, G. Batist2, P. Kavan2

Author affiliations

  • 1 Internal Medicine, University of Hawaii, 96813 - Honolulu/US
  • 2 Department Of Oncology, Mcgill University, Segal Cancer Centre - Jewish General Hospital, H3T 1E2 - Montreal/CA


Abstract 3127


Tumor location and pro-inflammatory microenvironment are both implicated in cancer progression and thus measures of these are thought to have important prognostic value. In this study, these readily available factors were examined in patients diagnosed with metastatic pancreatic adenocarcinoma (mPC) being treated in first line with FOLFIRINOX (FFX) or Gemcitabine with nab-Paclitaxol (GNP).


A cohort of 75 patients diagnosed with mPC between 2010 – 2016 and treated either with FFX or GNP first line were analyzed. The NLR was calculated based on the complete blood count obtained on the day of the first treatment. Cox proportional hazard models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) associating progression free survival to the patients’ demographics, treatment, clinical and pathological factors. NLR was treated as a continuous covariate.


Of the total patients (60% male, median age 69), 44 (58.7%) were treated with FFX. At the time of diagnosis, 20 (26.6%) presented with ECOG 0, 43 (57.3%) with primary disease at the head of the pancreas and 25 (33.3%) with liver metastasis. Median NLR at the diagnosis was 5.35 (range 0.9 – 28.3). Increasing NLR was a significant prognostic factor for shorter PFS using a univariate model (HR 1.08, CI: 1.009 – 1.15, P = 0.026). In a multivariate model, significant prognostic factors associated with shorter PFS included primary disease location at the pancreatic tail/body (HR 1.92, CI: 1.009 – 3.664, p = 0.047) and higher NLR (HR 1.11, CI: 1.038-1.189, P = 0.002).


Understanding the prognostic value of pro-inflammatory status and tumor location can allow clinicians to better manage the trajectory of patients with mPC.

Clinical trial identification

Legal entity responsible for the study

Lady Davis Institute and Segal Cancer Centre - Jewish General Hospital




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.